the blood-brain barrier and be converted into dopamine (C 8 H 11 NO 2 ) by the enzyme DOPA decarboxylase [4] .
In addition to motor symptoms, people suffering from PD present also a broad spectrum of non-motor symptoms (NMS) such as hyposmia, constipation, sleep-wake cycle disturbances, mood disorders, cognitive dysfunctions, hallucinations, delusions, personality changes, and multifaceted behavioral disorders, particularly impulse control disorders.
In some cases, NMS precede the occurrence of the motor phenomena, but in a majority of patients they appear with advancing disease and treatment. NMS significantly contribute to disability and disease burden for patients and caregivers [5] .
It remains unclear which PD non-motor symptoms are dependent on the dopaminergic deficit, are related to nondopaminergic systems, or are due to the dopaminergic therapy [6, 7] .
In recent years, an increasing number of studies focused on impulse control disorders (ICD) in persons with PD such as compulsive buying, obsessive hobbying, pathological gambling, medication abuse, sex addiction, and compulsive overeating [8] .
Treatment with dopaminergic agents improves PD motor symptoms but probably weakens the ability to control the compulsive repetition of rewarding behaviors.
Both l-DOPA and dopamine agonists (for example, bromocriptine, pramipexole, rotigotine, ropinirole) are associated with the onset of impulse control problems. However, an extensive survey of 3090 PD patients found that four ICD (compulsive buying, pathological gambling, sex addiction, binge eating disorder) were more common in patients treated with a dopamine agonist: 17.1% vs. 6.9% [9] .
Some findings suggested that chronic dopaminergic treatment-in particular with dopamine agonists-induces a down-regulation of striatal dopamine receptor type-2 (D 2 R) [10] . A recent systematic review also underlined the role of a predisposition [11] . Another systematic review confirmed that dopamine agonists could contribute to the development of ICDs that should be considered as multifactorial symptoms "involving drug-, patient-, and disease-related factors" [12] (p. 19). The study of ICD in PD patients offers a heuristic opportunity to explore the role of different dopaminergic projections and dopamine receptors in impulse control difficulties and, in particular, in binge eating, food craving, and food addiction that are still controversial concepts with uncertain implications for etiology and treatment [13] [14] [15] .
Many clinical questions arise. Is binge eating disorder (BED) different in PD? Could BED-oriented cognitivebehavioral therapy be useful also in BED with PD? How could we prevent disordered eating behaviors and weight gain in PD?
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